Loading
When a resistance mutation first appears in the blood, the current drug is often still controlling most of the tumour. Adding a second drug rather than swapping may keep both under control.
Most ctDNA-guided strategies switch therapy at molecular progression. Because the resistant clone is usually a minority at that point, switching abandons control of the sensitive majority. An additive strategy keeps the backbone and adds a mechanism-matched agent when a specific resistance alteration crosses a threshold in plasma, with the aim of suppressing both populations.
One of the most cited trial reports Europe PMC returns for Osimertinib in Non-small-cell lung cancer, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
Anyone diagnosed with advanced lung cancer should have EGFR testing before treatment, because osimertinib as the first drug gives the longest disease control, protects the brain, and is well tolerated. Chemotherapy is not the first step for these patients. The remaining questions are whether to intensify upfront (adding chemotherapy or amivantamab) and how to treat resistance when it develops.
One of the most cited trial reports Europe PMC returns for Osimertinib in Non-small-cell lung cancer, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
Shares Overall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC, Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer, FLAURA: osimertinib as first treatment for EGFR-mutated lung cancer, Osimertinib.
Shares Overall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC, Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer, FLAURA: osimertinib as first treatment for EGFR-mutated lung cancer, Osimertinib.
Shares Overall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC, Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer, FLAURA: osimertinib as first treatment for EGFR-mutated lung cancer, Osimertinib.
Shares Molecular-progression switching beyond ESR1, Osimertinib, Acquired resistance to every therapy, Liquid biopsy (ctDNA).
Shares Amivantamab, MET, Osimertinib, EGFR.
Shares Amivantamab, MET, Osimertinib, EGFR.
Shares FLAURA: osimertinib as first treatment for EGFR-mutated lung cancer, Amivantamab, MET, Osimertinib.
Shares Overall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC, FLAURA: osimertinib as first treatment for EGFR-mutated lung cancer, Osimertinib, Acquired resistance to every therapy.